United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

terumo bct ltd - mannitol - infusion - 200mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

terumo bct ltd - mannitol - infusion - 100mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - canakinumab 150 mg/ml - solution for injection - 150 mg/ml - active: canakinumab 150 mg/ml excipient: histidine mannitol polysorbate 80 water for injection - ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (caps), in adults and children aged 2 years and older including: · familial cold autoinflammatory syndrome (fcas) /familial cold urticaria (fcu) · muckle-wells syndrome (mws) · neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca).

United States - English - NLM (National Library of Medicine)

hospira, inc. - sorbitol (unii: 506t60a25r) (sorbitol - unii:506t60a25r), mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - sorbitol 2.7 g in 100 ml - sorbitol-mannitol irrigation is indicated for use as a urologic irrigating fluid during transurethral prostatic resection and other transurethral surgical procedures. not for injection by usual parenteral routes. do not use in patients with anuria.

United States - English - NLM (National Library of Medicine)

icu medical inc. - sorbitol (unii: 506t60a25r) (sorbitol - unii:506t60a25r), mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - sorbitol-mannitol irrigation is indicated for use as a urologic irrigating fluid during transurethral prostatic resection and other transurethral surgical procedures. not for injection by usual parenteral routes. do not use in patients with anuria.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - avelumab, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: polysorbate 20; mannitol; glacial acetic acid; sodium hydroxide; water for injections - bavencio is indicated for the treatment of adults and paediatric patients 12 years and older with metastatic merkel cell carcinoma (mmcc). this indication is approved based on tumour response rate, duration of response in a single arm study.,bavencio is indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (uc) whose disease has not progressed with first-line platinum-based induction chemotherapy.,bavencio in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (rcc).

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - mannitol - solution for infusion - 10 percent - solutions producing osmotic diuresis; mannitol

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mannitol -

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - gemcitabine - powder for solution for infusion - gemcitabine 38 mg/ml - antineoplastic agents

Canada - English - Health Canada

fresenius kabi canada ltd - mannitol - solution - 25% - mannitol 25% - osmotic diuretics